MSS CRC Immunotherapy: What the Trial History Tells You

A CrisPRO Intelligence Brief for Next-Generation MSS CRC Program Partners

Prepared by: CrisPRO Platform Intelligence
Indication: MSS/pMMR Metastatic Colorectal Cancer
Purpose: Competitive landscape orientation for prospective program partners

What this document is. CrisPRO maintains a continuously updated, evidence-graded intelligence map of every meaningful immunotherapy trial in MSS CRC. This brief gives you a structured view of what has been tried, what has failed, and — critically — where the separable biology lives. It is the foundation for any serious biomarker or trial design conversation about a first-line MSS CRC program.

THE CORE PROBLEM: WHY MSS CRC HAS DEFEATED EVERY BROAD IO APPROACH

MSS/pMMR CRC constitutes approximately 95% of all metastatic CRC. It is structurally resistant to checkpoint immunotherapy. This is not a dosing problem or a combination problem — it is a biology problem. The tumor microenvironment (TME) in MSS CRC is a layered, redundant immunosuppressive architecture. Understanding exactly which layers are operative in which patients is the prerequisite for any rational IO strategy.

CrisPRO has decoded the failure modes across more than 25 trials. The pattern is consistent.

TIER 1: CHECKPOINT BLOCKADE — THE PRIMARY FAILURE LANDSCAPE

What happened: Every major checkpoint inhibitor trial in unselected MSS CRC failed.

What this means for a new program: CheckMate 9X8 is the most important data point for any first-line MSS CRC program using mFOLFOX6 + bevacizumab as backbone. PD-1 blockade added to this exact backbone failed to improve PFS. This is not a reason to abandon the backbone — it is a reason to require a mechanistically distinct immune priming strategy, not just checkpoint release.

The TMB-H lesson: High tumor mutational burden is not sufficient for MSS CRC. The CRC TME is uniquely immunosuppressive beyond mutational load. TGF-β-driven stromal exclusion and liver metastasis-induced systemic tolerance override neoantigen burden. A program that relies on TMB-H enrichment alone will fail.

TIER 2: CHEMO + IO AND ANTI-VEGF + IO — MARGINAL SIGNALS, IMPORTANT SUBGROUPS

What happened: Adding IO to chemotherapy or anti-VEGF backbones produced marginal or no benefit in unselected MSS CRC — but subgroup analyses revealed separable biology.

Key trials and what they taught:

AtezoTRIBE (FOLFOXIRI + bevacizumab ± atezolizumab, 1L):

• ITT PFS benefit driven by MSI-H patients
• pMMR/MSS subgroup: PFS HR 0.86 — not significant
• But: Immunoscore-IC high pMMR patients showed PFS HR ~0.50. DetermaIO gene signature high showed HR ~0.45
• Lesson: ~20–30% of pMMR/MSS CRC is immune-inflamed. This subgroup exists. It is not being selected for.

CCTG CO.26 (Durvalumab + tremelimumab, refractory):

• Overall OS HR 0.73 — modest, not significant at pre-specified threshold
• pTMB ≥28 variants/Mb subgroup: OS HR 0.34 — a real signal in ~10–15% of MSS CRC
• No liver metastases subgroup: HR ~0.50 vs. ~0.90 with liver metastases
• Lesson: Liver metastasis is not just a prognostic factor — it is an immunological barrier that abolishes IO benefit

MEDITREME (Durvalumab + tremelimumab + mFOLFOX6, 1L RAS-mutant):

• No randomized control; ORR consistent with FOLFOX alone
• But: Immune biomarker analysis identified a ~25% subgroup with high baseline CD8+ infiltration and low TGF-β that showed separable biology
• Lesson: The responding subgroup in MSS CRC is identifiable at baseline. The problem is that no trial has prospectively enrolled for it.

TIER 3: VACCINE AND ANTIGEN-DIRECTED APPROACHES — PHARMACODYNAMIC ACTIVITY WITHOUT CLINICAL BENEFIT

What happened: Every vaccine approach in MSS CRC has generated peripheral immune responses. None has generated clinical benefit in unselected populations.

The critical pattern: Peripheral T-cell induction is achievable. Tumor regression is not. The gap between peripheral immune activation and tumor-directed immunity is the defining unsolved problem in MSS CRC IO.

What GRANITE taught about trial design: The low-ctDNA subgroup (patients with minimal residual disease at maintenance initiation) showed HR 0.50 — a meaningful signal that was buried in the unselected ITT analysis. This is the GRANITE lesson for any MSS CRC vaccine program: biomarker enrichment is not optional. It is the difference between a signal and a null result.

What AdCEA + avelumab taught about backbone design: This trial used the same backbone as BreAK CRC-001 (mFOLFOX6 + bevacizumab) with a CEA-directed vaccine and PD-L1 blockade. It was terminated for futility. The design precedent (safety lead-in, bevacizumab sequencing) is informative. The efficacy framing as a positive precedent is not valid.

TIER 4: WHERE THE SEPARABLE BIOLOGY LIVES — THE REGONIVO/RIN SIGNAL

The most important signal in MSS CRC IO today:

REGONIVO (regorafenib + nivolumab, Japan):

• Overall MSS CRC ORR: 33% — a striking initial signal
• All 8 responders had NO liver metastases

REGONIVO Phase 2 (US):

• Overall ORR: 7% — failed to replicate Japanese results
• Non-liver-metastatic subgroup ORR: 22%
• Liver-metastatic ORR: ~0%

RIN (regorafenib + ipilimumab + nivolumab):

• Non-liver-metastatic cohort ORR: ~40%; median OS 20 months — some complete responses, potential cures
• Liver-metastatic ORR: ~5%

What this means: Non-liver-metastatic MSS CRC is a biologically distinct subgroup with genuine IO responsiveness. It represents ~20–25% of mCRC patients. It has never been prospectively enrolled for in a first-line trial. Any program that does not stratify by liver metastasis status is enrolling the wrong patients.

THE FIVE STRUCTURAL LESSONS FOR A NEXT-GENERATION MSS CRC IO PROGRAM

CrisPRO's synthesis of the trial history produces five non-negotiable design principles:

1. Biomarker enrichment is not optional.
Every unselected MSS CRC IO trial has failed. Every subgroup analysis has found a responding minority. The question is not whether a responding subgroup exists — it does. The question is whether you enroll for it.

2. Liver metastasis status is the single most accessible enrichment criterion.
It is standard staging data (CT/MRI). It predicts IO response better than TMB, PD-L1, or any molecular biomarker. Non-liver-metastatic MSS CRC is the highest-probability subgroup for any IO approach.

3. Peripheral immune activation ≠ clinical benefit.
DTH responses, T-cell induction, and ctDNA changes are necessary but not sufficient. The TME suppression mechanisms (TGF-β exclusion, MDSC burden, Kupffer cell-mediated T-cell elimination) must be addressed, not just the peripheral immune compartment.

4. Single-arm designs in unselected MSS CRC cannot demonstrate vaccine-attributable benefit.
mFOLFOX6 ± bevacizumab achieves ~80–90% DCR and ~50–55% 12-month PFS in first-line mCRC. Any single-arm trial will be statistically indistinguishable from SOC effect without a pharmacodynamic endpoint mechanistically linked to the vaccine.

5. The backbone matters.
CheckMate 9X8 tested PD-1 blockade on the mFOLFOX6 + bevacizumab backbone and failed. This is not a reason to abandon the backbone — it is a reason to require a mechanistically distinct immune priming strategy. The backbone creates a vascular normalization window (peak CD8 infiltration at cycle 2, ~days 14–28) that a well-timed vaccine could exploit. Timing is not a detail — it is a mechanism.

WHAT CRISPRO BRINGS TO THIS LANDSCAPE

CrisPRO has built a continuously updated, evidence-graded intelligence map of the MSS CRC IO trial history. For a next-generation MSS CRC program partner, this translates to:

• Competitive positioning analysis: Where does your program sit relative to the 25+ trials that have failed, and what makes it mechanistically distinct?
• Subgroup biology mapping: Which of the separable biology signals (non-liver-metastatic, Immunoscore-IC high, pTMB-high, low-TGF-β) is your program most likely to engage?
• Trial design intelligence: What does the GRANITE, REGONIVO, and CO.26 experience tell you about how to design a Phase IIa that can detect a real signal?
• Historical control benchmarking: What is the right historical control for your primary endpoint, and how do you pre-specify it to be credible to regulators?

The trial history is not a graveyard. It is a map. CrisPRO reads it so you don't have to start from zero.

This document represents a curated subset of CrisPRO's MSS CRC intelligence map. Full trial-level data, subgroup analyses, biomarker correlation matrices, and design templates are available under engagement. Contact CrisPRO to discuss how this intelligence applies to your specific program.